Latest & greatest articles for pregabalin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregabalin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregabalin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregabalin

81. High dose pregabalin is effective for the treatment of generalised anxiety disorder Full Text available with Trip Pro

High dose pregabalin is effective for the treatment of generalised anxiety disorder High dose pregabalin is effective for the treatment of generalised anxiety disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High dose pregabalin is effective for the treatment of generalised anxiety disorder Article Text Therapeutics High dose pregabalin is effective for the treatment of generalised anxiety disorder Free Raymond Pary , MD

2005 Evidence-Based Mental Health

82. Lyrica (Pregabalin) Capsules

Lyrica (Pregabalin) Capsules Drug Approval Package: Lyrica (Pregabalin) NDA #021724 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Lyrica (Pregabalin) Capsules Company: Pfizer Inc. Application No.: 021724 Approval Date: 06/10/2005 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: January 23, 2008 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing

2005 FDA - Drug Approval Package

83. Pregabalin for peripheral neuropathic pain

Pregabalin for peripheral neuropathic pain Pregabalin for peripheral neuropathic pain Pregabalin for peripheral neuropathic pain Hadj Tahar A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hadj Tahar A. Pregabalin for peripheral neuropathic pain. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2005: 4 (...) Authors' objectives The aim of this report is to review the available information on the use of pregabalin (Trade Mark: Lyrica), an anticonvulsant drug, in the treatment of adults with peripheral neuropathic pain (NeP). Authors' conclusions The costs associated with pregabalin treatment may not compare favourably with that of generic gabapentin. However, gabapentin is not approved for the treatment of NeP by Health Canada. While pregabalin appears to be an effective treatment for NeP

2005 Health Technology Assessment (HTA) Database.

84. Lyrica (Pregabalin)

Lyrica (Pregabalin) Drug Approval Package: Lyrica (Pregabalin) NDA #021446 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Lyrica (Pregabalin) Capsules Company: Pfizer Gloval Research & Development Application No.: 021446 Approval Date: 12/30/2004 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 192005 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing information in different file formats

2004 FDA - Drug Approval Package